LungÕ 2026 – Virtual Global Congress on Lung Oncology
ASTRIDE Bridges the Gap: Serplulimab Matches 32% Two-Year Survival in U.S. Patients with Small Cell Lung Cancer
Daniel Malarek and a Wish for Oncology: A Future Where Breakthroughs Reach Every Patient
London Global Cancer Week 2026: Highlights From November 2–4
Perioperative Ivonescimab Shows Promising Pathological Responses in Resectable NSCLC: Phase II Trial Reports 70.1% MPR and 50.7% pCR
BeOne Medicines’ Zanubrutinib Combination Gains FDA Priority Review for First-Line Mantle Cell Lymphoma
From TAILORx to OPTIMA: Genomic Testing Expands Chemotherapy De-escalation in Higher-Risk HR-Positive Breast Cancer
Expert Discussion at COGC 2026: The Right First Investments in Precision Oncology
OncoDaily Lung is OncoDaily’s dedicated platform for lung cancer, highlighting the latest advances across the rapidly evolving field of thoracic oncology. The platform covers the full spectrum of lung malignancies, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and other thoracic cancers. From clinical trial results and ongoing research to FDA and EMA approvals, updated treatment guidelines, emerging therapies, biomarker discoveries, precision medicine, and major conference data, OncoDaily Lung keeps readers informed about developments shaping the field. The platform also features expert interviews and perspectives from leading specialists in lung and thoracic oncology.
